Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVARTIS AG : Bernstein sticks Neutral

07/21/2021 | 03:18pm EDT

Bernstein's research confirms his advice and maintains his neutral opinion on the stock. The target price remains set at CHF 92.


ę MarketScreener with dpa-AFX Analyser 2021
All news about NOVARTIS AG
05:26aNOVARTIS AG : Buy rating from UBS
MD
08/03IONIS PHARMACEUTICALS : discovered pelacarsen continues to advance as potential ..
AQ
08/03BAUSCH HEALTH : Reports Q2 Revenue US$2.1 Billion; Plans To Pursue An IPO of Sol..
MT
08/03NOVARTIS : announces lift of partial clinical trial hold and plans to initiate a..
PU
08/03Novartis Gets FDA Approval to Proceed With Trials for Muscular Atrophy Treatm..
DJ
08/03NOVARTIS : Says FDA Lifts Partial Hold on Clinical Trial of Spinal Muscular Atro..
MT
08/03NOVARTIS : to Launch New Study of Neuromuscular Disease Drug After US FDA Lifts ..
MT
08/03PRESS RELEASE : Novartis announces lift of partial -2-
DJ
08/03PRESS RELEASE : Novartis announces lift of partial clinical trial hold and plans..
DJ
08/03Novartis announces lift of partial clinical trial hold and plans to initiate ..
DJ
More news
Financials (USD)
Sales 2021 51 982 M - -
Net income 2021 9 881 M - -
Net Debt 2021 22 970 M - -
P/E ratio 2021 20,2x
Yield 2021 3,56%
Capitalization 225 B 225 B -
EV / Sales 2021 4,77x
EV / Sales 2022 4,46x
Nbr of Employees 109 000
Free-Float 87,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 92,35 $
Average target price 105,60 $
Spread / Average Target 14,4%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-0.20%224 638
JOHNSON & JOHNSON10.81%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.24.10%255 703
ELI LILLY AND COMPANY51.62%232 701
NOVO NORDISK A/S36.67%213 138